Analyst Price Targets — CUE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 15, 2024 1:59 pm | Maury Raycroft | Jefferies | $4.00 | $1.29 | StreetInsider | Cue Biopharma (CUE) PT Lowered to $4 at Jefferies |
| July 26, 2024 6:14 am | Reni Benjamin | JMP Securities | $2.00 | $0.70 | TheFly | Cue Biopharma price target lowered to $2 from $15 at JMP Securities |
| March 13, 2024 2:52 am | Maury Raycroft | Jefferies | $6.00 | $2.15 | StreetInsider | Jefferies Starts Cue Biopharma (CUE) at Buy, 'Following Nature's "Cues" W/ Targeted IL-2 Therapy' |
| November 20, 2022 6:23 pm | Edward Tenthoff | Piper Sandler | $7.00 | $3.22 | TheFly | Cue Biopharma initiated with an Overweight at Piper Sandler |
Latest News for CUE
Cue Biopharma (NASDAQ: CUE) held its annual meeting of stockholders virtually, with Interim President and Chief Executive Officer Lucinda Warren presiding and outlining four proposals put before shareholders, including director elections, auditor ratification, executive compensation, and a reverse stock split amendment. Meeting setup and attendance Warren opened the meeting and introduced key participants, including…
The biopharmaceutical company is developing injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body.
Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases BOSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, an industry veteran who has served as Cue Biopharma's chief financial and business officer…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CUE.
U.S. House Trading
No House trades found for CUE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.